Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.19
(
0.67%
)
Bitcoin
76,734.76
(
-0.87%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 45571

Monday, 04/23/2007 3:08:39 AM

Monday, April 23, 2007 3:08:39 AM

Post# of 257580
QLTI’s CEO must be a ‘half-full’ kind of guy:

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070423:MTFH92823_2...

>>
Visudyne sales in the United States for the quarter were about $8.4 million…

“Sales of Visudyne in the U.S. appear to have stabilized in January and grew in February and March due to increases in market share of combination therapy,” Chief Executive Bob Butchofsky said.
<<

Stabilized, perhaps, but utterly irrelevant to the future of AMD treatment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today